NCT04416854 is a Phase 3 clinical trial of resection of primary tumor in Metastatic Colon Cancer, sponsored by Fudan University.

Who is sponsoring NCT04416854?

NCT04416854 is sponsored by Fudan University.

What drugs are being tested in NCT04416854?

Interventions in NCT04416854: resection of primary tumor, XELOX, mFOLFOX6.

What condition does NCT04416854 study?

NCT04416854 studies Metastatic Colon Cancer, Surgery.

Is NCT04416854 still recruiting?

NCT04416854 is currently status unknown. Last updated 4 June 2020.

Last reviewed 2020-06-04 · How we verify

NCT04416854

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer

Status unknown Phase 3 Last updated 4 June 2020

What this trial tests

Phase 3 trial testing resection of primary tumor in Metastatic Colon Cancer in 627 participants. Status unknown.

Timeline

1 April 2020

Primary endpoint
31 December 2023

31 December 2025

Quick facts

Lead sponsor	Fudan University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	627
Start date	1 April 2020
Primary completion	31 December 2023
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

resection of primary tumor
XELOX — full drug profile →
mFOLFOX6

Conditions studied

Metastatic Colon Cancer — all drugs for Metastatic Colon Cancer →
Surgery — all drugs for Surgery →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Metastatic Colon Cancer or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this trial is to evaluate the value of palliative primary tumor resection in colon cancer patients with initially unresectable metastases and a positive response to induction chemotherapy which depends on gene testing. The primary endpoint is to evaluate overall survival.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Primary tumor resection for asymptomatic colorectal cancer patients with synchronous unresectable metastases: a meta-analysis of randomized controlled trials and case-matched studies.
Huang J, Zhou J, Zhang P, Wu Q, et al · · 2024 · cited 1× · PMID 39105876 · DOI 10.1007/s00423-024-03414-9

Verify or expand the search:

Other recruiting trials for Metastatic Colon Cancer

Currently open trials in the same condition.

NCT06202183 — Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial · NA · recruiting
NCT05848739 — A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors · Phase 1 · recruiting
NCT05714124 — Liver Embolization Approaches for Tumor Management · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04416854 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 4 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04416854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing